Navigation Links
BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
Date:1/3/2008

tive Officer of BioMarin. "This structure will also reduce management time and provide stronger incentives for each company to maximize the efficiency of its own operations related to Aldurazyme. Lastly, this new structure allows the companies to collaborate and equally share costs on research projects which could lead to important advances for MPS I patients."

About MPS I

MPS I is a rare, progressive, heterogeneous, debilitating disease caused by a deficiency of the enzyme alpha L-iduronidase that affects an estimated 3,000 to 4,000 people worldwide, including approximately 1,000 in the United States. Patients who lack this enzyme accumulate a carbohydrate called glycosaminoglycan (GAG) in tissues and organ systems. A majority of patients die before adulthood due to a wide range of problems related to the disease, including progressive damage to the heart, lungs, liver, and kidneys. Aldurazyme addresses the underlying cause of MPS I by replacing the missing enzyme through a weekly infusion. More information about MPS I can be found at http://www.mps1disease.com.

About Aldurazyme

Aldurazyme is indicated for patients with the Hurler and Hurler-Scheie forms of MPS I, and for Scheie patients with moderate to severe symptoms. The risks and benefits of treating mildly affected patients with the Scheie form have not been established. Aldurazyme has not been evaluated for effects on the central nervous system manifestations of the disorder. More information on Aldurazyme can be found at http://www.aldurazyme.com.

The most common side effects associated with treatment with Aldurazyme were upper respiratory tract infection, rash, and injection site reaction. The most common adverse reactions requiring treatment were infusion-related hypersensitivity reactions including flushing, fever, headache, and rash. The most serious adverse rea
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease
2. BioMarin to Present at the Rodman & Renshaw 9th Annual Healthcare Conference
3. BioMarin to Present at the BioCentury NewsMakers Conference
4. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
5. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
6. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
7. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
8. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
9. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
10. Genzyme Launches Cholestagel(R) in Europe
11. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... --  Intrexon Corporation (NYSE: XON ) today ... after the market closes on May 11, 2015.  The ... 5:30 PM ET to discuss the results and provide ... may be accessed by dialing 1-888-346-3959 (Domestic US) and ... Call."  Participants may also access the live webcast through ...
(Date:5/1/2015)... - BioAmber Inc. (NYSE: BIOA ), an industrial ... priced an underwritten registered offering of 3,900,000 shares of ... share, and granted the underwriters in the offering a ... shares of its common stock. The gross proceeds to ... to close on May 6, 2015, subject to customary ...
(Date:5/1/2015)... ALBANY, N.Y. , May 1, 2015 ... today that William S. Marth , AMRI,s President ... of America Merrill Lynch 2015 Health Care Conference on ... A live audio webcast of the presentation can ... http://ir.amriglobal.com/events.cfm?CalendarID=2          The webcast will be ...
(Date:4/30/2015)... , April 30, 2015   Tamir Biotechnology , ... an update on its Ebola antiviral therapy program. ... candidates, TMR004, is currently being evaluated and considered by ... battle against Ebola. During the first quarter of 2015, ... Meeting To Accelerate The Evaluation of Potential Treatments and ...
Breaking Biology Technology:Intrexon to Announce First Quarter 2015 Financial Results on Monday, May 11, 2015 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 3AMRI to Present at the Bank of America Merrill Lynch 2015 Health Care Conference 2Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 2Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 4
... Imaging,Diagnostic Systems, Inc., (OTC Bulletin Board: IMDS), ... I returned to the company three months ago to,assume ... Board; we have,received many phone calls from our shareholders ... my first priority, I have,recently secured a tiered debenture ...
... Conn., Aug. 5 Marinus Pharmaceuticals, a,developer of ... disorders, has appointed John Krayacich as president,and chief ... leading,the company,s drug and business development for ganaxolone, ... and chelerythrine, a pre-clinical,schizophrenia candidate., Mr. Krayacich ...
... Group, P.A., Deliver Faster Recovery,Fewer Complications for ... Aug. 5 Thoracic Group, P.A., (http://www.thoracicgroup.com ... services,and a national leader of minimally-invasive video ... completion of its 5,000th VATS,surgical procedure. Highly ...
Cached Biology Technology:CEO's Letter to Shareholders of Imaging Diagnostic Systems, Inc. 2CEO's Letter to Shareholders of Imaging Diagnostic Systems, Inc. 3CEO's Letter to Shareholders of Imaging Diagnostic Systems, Inc. 4Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer 2Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer 3Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer 4Renowned NJ-Based Video Assisted Thoracic Surgery (VATS) Team Completes 5,000th Successful Procedure 2Renowned NJ-Based Video Assisted Thoracic Surgery (VATS) Team Completes 5,000th Successful Procedure 3
(Date:4/10/2015)... DUBLIN , April 10, 2015 ... the addition of the "Security Competitive Profiles - ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , NEC will continue to ... solutions to the market, with a company focus on ... solution anticipated. Winning opportunities in the ...
(Date:4/8/2015)...  Infinisource, a leading provider of SaaS-based Human Capital ... leading supplier of biometric identification and security solutions, ... advanced biometrically-enabled time clock, the companies announced today. ... setting a bold, new standard for the collection ... and mid-size employer. When connected to the iSolved ...
(Date:4/2/2015)... In the current eight ... the strongest competitors, showing outstanding performance in recognition ... is capable of a throughput of 5.000.000 fingerprints ... be ten times faster than most competitors and ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) , ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... Catching a football. Maneuvering through a room full of ... fore. Most would agree these seemingly simple actions require us ... of Cognitive Science at Rensselaer Polytechnic Institute Mark Changizi argues ... It takes our brain nearly one-tenth of a second to ...
... hold empirical knowledge that tuna aggregate under floating objects, ... or even large marine mammals. There is still no ... 20 years have seen purse-seine fishery operators take advantage ... floating rafts equipped with buoys which act as FADs. ...
... in green tea may be able to stave off ... (OSA), according to a new study published in the ... American Journal of Respiratory and Critical Care Medicine. ... through drinking water, on rats who were intermittently deprived ...
Cached Biology News:Crystal (eye) ball: Study says visual system equipped with 'future seeing powers' 2Crystal (eye) ball: Study says visual system equipped with 'future seeing powers' 3Does fishing on drifting fish aggregation devices endanger the survival of tropical tuna? 2Does fishing on drifting fish aggregation devices endanger the survival of tropical tuna? 3Green tea compounds beat OSA-related brain deficits 2
... PCR System is the only PCR system ... and every time. It provides accuracy, consistency, ... source or the property of the DNA ... Enzyme Mix, a unique blend of thermostable ...
ID clarifier: With ethidium bromide (50 μg/ml)...
Extremely high efficiency packaging extracts useful for transfecting our EpiFOS™ or CopyControl™ Fosmids, or any DNA vector with cos sites. A tremendous value when conpared to the competition...
... Buffer is a convenient, premixed, ... samples and Perfect RNA Markers. ... no dilution and is suitable ... Simply mix equal volumes of ...
Biology Products: